Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib Frontline Risk Adapted
NCT07804901Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib, dasatinib in chronic myeloid leukemia (CML). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
asciminibdasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07804901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07804901.